Emcure Pharmaceuticals: Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited,…
Emcure Pharmaceuticals (EMCURE) filed a disclosure titled "Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals…". The company is valued at…
What happened
Emcure Pharmaceuticals (EMCURE) filed a disclosure with the exchanges on 12 October 2026 at 10:29 AM titled "Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals…".
Company snapshot
Emcure Pharmaceuticals is a mid-cap company in the Healthcare sector, with a market value of about ₹35,662 crore.
The stock last traded at ₹1,880.1, against a 52-week range of ₹1,306.5–₹2,100.7 (10.5% below the high).
Before this filing the shares had moved −4.2% over the month and +2.2% over three months. Average daily turnover over the last 20 sessions was about ₹38.87 crore.
Promoters held 77.83% at the end of Q1 FY27, down 0.04% points from the previous quarter; 0.04% of promoter shares were pledged. Foreign institutions owned 4.88% and domestic institutions 8.46%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 2,101 | 207 | 10.92 |
| Q2 FY26 | 2,270 | 243.5 | 12.85 |
| Q3 FY26 | 2,363 | 230.5 | 12.16 |
| Q4 FY26 | 2,470 | 243.4 | 12.84 |
| Q1 FY27 | 2,580 | 294 | 15.5 |
What history shows
BCEIE's records show 4 previous m&a filings from the company since May 2026.
After those filings, the stock fell 0.6% on average the next trading day and was up 2.1% on average after five days (3 filings with price data).
Across 139 similar disclosures by other Healthcare companies, shares moved +0.7% on average the next day and +1.0% over five days; 60% of them rose the next day.
Market-wide, 2,032 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 22 Jul 2026 | M&A | −0.4% | +1.1% |
| 13 Jul 2026 | M&A | −0.2% | +7.3% |
| 3 Jul 2026 | M&A | −1.2% | −2.3% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
- Emcure Pharmaceuticals (NSEI:EMCURE) Stock Forecast & Analyst Predictions
- Emcure Pharmaceutica Share Price Today, Emcure Pharmaceutica Stock Price Live NSE/BSE Updates
- Rajiv Dua Joins Emcure Pharmaceuticals as GM & Head – PMO & Program Management, Gennova Biopharma
- Emcure Pharmaceuticals faces ₹57.74 crore income-tax penalty for FY15-FY21
- Emcure Pharmaceuticals (NSE:EMCURE): What Does the Rs 57.74 Crore Tax Penalty Order Mean?
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.